Anti-CCP antibody measurements are valuable tools that can aid in the diagnosis of RA and predict the development of the disease; they are associated with disease progression and more severe disease. Anti-CCP measurements facilitate early diagnosis of RA, allowing for early initiation of therapy.
An aCCP antibody test may be ordered along with or following a rheumatoid factor (RF) test to help diagnose rheumatoid arthritis and to assess the severity and probable course of the disease (prognosis). CCP antibody may also be ordered to help evaluate the likely development of RA in people with undifferentiated arthritis – those whose symptoms suggest but do not yet meet the American College of Rheumatology (ACR) criteria for RA. According to ACR, approximately 95% of those with a positive CCP antibody will meet the criteria of RA in the future.1
Both the American College of Rheumatology (ACR) and the European League Against Rheumatism Collaborative Initiative (EULAR) recommend the use of anti-CCP testing for RA classification and management of early arthritis.2-3
The anti-CCP assay on the IMMULITE® 2000/2000 XPi and ADVIA Centaur XP, CP, and XPT Systems offers excellent specificity for differential assessment of RA.
2. EULAR recommendations for the management of early arthritis: report of a task force of the ESCISIT. Ann Rheum Dis 2007 66:34-45
3.2010 Rheumatoid Arthritis Classification Criteria. D Aletaha, T Neogi et al. Arthritis and Rheumatism, Vol 62, No. 9 September 2012. pp 2569-2581